Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference
Sana Biotechnology (NASDAQ: SANA), a company specializing in engineered cell therapies, has announced its participation in the BofA Securities 2025 Healthcare Conference. The company's President and CEO, Steve Harr, will deliver a business overview and update during a presentation scheduled for May 13, 2025, at 9:20 a.m. PT. The presentation will be accessible via webcast on Sana's Investor Relations website, with a replay available for 30 days after the event.
Sana Biotechnology (NASDAQ: SANA), un'azienda specializzata in terapie cellulari ingegnerizzate, ha annunciato la sua partecipazione alla BofA Securities 2025 Healthcare Conference. Il Presidente e CEO dell'azienda, Steve Harr, presenterà una panoramica aziendale e un aggiornamento durante una presentazione prevista per il 13 maggio 2025 alle 9:20 PT. La presentazione sarà accessibile tramite webcast sul sito di Relazioni con gli Investitori di Sana, con una replica disponibile per 30 giorni dopo l'evento.
Sana Biotechnology (NASDAQ: SANA), una empresa especializada en terapias celulares diseñadas, ha anunciado su participación en la Conferencia de Salud 2025 de BofA Securities. El presidente y CEO de la compañía, Steve Harr, ofrecerá una visión general del negocio y una actualización durante una presentación programada para el 13 de mayo de 2025 a las 9:20 a.m. PT. La presentación estará disponible por webcast en el sitio web de Relaciones con Inversionistas de Sana, con una repetición accesible durante 30 días después del evento.
Sana Biotechnology (NASDAQ: SANA)는 엔지니어드 세포 치료를 전문으로 하는 회사로, BofA Securities 2025 Healthcare Conference에 참여할 것이라고 발표했습니다. 회사의 사장 겸 CEO인 Steve Harr는 2025년 5월 13일 오전 9시 20분(태평양 시간)에 예정된 발표에서 사업 개요 및 최신 정보를 전달할 예정입니다. 발표는 Sana 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있으며, 이벤트 종료 후 30일간 다시보기 서비스가 제공됩니다.
Sana Biotechnology (NASDAQ : SANA), une entreprise spécialisée dans les thérapies cellulaires ingénierées, a annoncé sa participation à la BofA Securities 2025 Healthcare Conference. Le président-directeur général de l'entreprise, Steve Harr, présentera un aperçu des activités et une mise à jour lors d'une présentation prévue le 13 mai 2025 à 9h20 PT. La présentation sera accessible en webcast sur le site des relations investisseurs de Sana, avec une rediffusion disponible pendant 30 jours après l'événement.
Sana Biotechnology (NASDAQ: SANA), ein Unternehmen, das sich auf entwickelte Zelltherapien spezialisiert hat, hat seine Teilnahme an der BofA Securities 2025 Healthcare Conference angekündigt. Der Präsident und CEO des Unternehmens, Steve Harr, wird während einer Präsentation am 13. Mai 2025 um 9:20 Uhr PT einen Überblick über das Geschäft und ein Update geben. Die Präsentation wird über einen Webcast auf der Investor-Relations-Website von Sana zugänglich sein, mit einer Wiederholung, die 30 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2025 Healthcare Conference at 9:20 a.m. PT on Tuesday, May 13, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.
The webcast will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. A replay of the presentation will be available at the same location for 30 days following the conference.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA, and Bothell, WA. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; the Company’s participation at the BofA Securities 2025 Healthcare Conference; and the subject matter of the Company’s presentation at the conference. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated May 8, 2025. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
FAQ
When is Sana Biotechnology (SANA) presenting at the BofA Securities Healthcare Conference 2025?
Who will be presenting for Sana Biotechnology (SANA) at the BofA Securities Conference?
How can investors access Sana Biotechnology's (SANA) presentation at the BofA Securities Conference?
How long will Sana Biotechnology's (SANA) presentation replay be available?
